EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Performance of Circulating Inflammatory Biomarkers and Krebs von den Lungen 6 for Predicting Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease

Keina Yomono iD, Suiyuan Huang, Dinesh Khanna iD, Masataka Kuwana iD

ACR Open Rheumatology · 2026-03 · 8 (3)

DOI: 10.1002/acr2.90013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 17.03.2026. Verfasst von Keina Yomono und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health, Labour and Welfare.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the predictive performance of inflammatory biomarkers, including C‐reactive protein (CRP) and Krebs von den Lungen 6 (KL‐6), for the development of progressive pulmonary fibrosis (PPF) in patients with systemic sclerosis (SSc)–associated interstitial lung disease (ILD).

Methods

A total of 135 patients with SSc‐ILD were retrospectively selected from a single‐center prospective registry. The predictive performance of individual biomarkers and their combinations for PPF development was evaluated using area under the curve (AUC) values from receiver operating characteristic analysis. A time‐varying Cox proportional hazards model was used to assess the prognostic significance of near‐term dynamic changes in KL‐6 levels.

Results

During a median follow‐up of 43 months, 26 patients (19%) developed PPF. Baseline CRP and KL‐6 levels did not correlate with each other. Patients with high baseline KL‐6 (≥1,000 U/mL) had more extensive ILD and reduced forced vital capacity compared to those with low levels. Baseline KL‐6 demonstrated superior predictive performance for ILD progression (with the highest AUC) compared to CRP. The PPF‐free survival rate was significantly lower in the high KL‐6 group than in the low KL‐6 group ( P = 0.02). A doubling of KL‐6 levels at any time from 12 months to 6 months before PPF assessment or censoring was associated with a significantly higher risk of subsequent PPF development (hazard ratio 1.66 [95% confidence interval 1.13–2.45]).

Conclusion

Baseline KL‐6 and CRP values identify distinct subsets of SSc‐ILD patients. Elevated baseline KL‐6 levels and a significant rise over the subsequent six months are associated with an increased risk of PPF, supporting their potential as prognostic biomarkers. image

Autor:innen und Institutionen

  • Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
  • Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor.
  • Scleroderma/Myositis Centre of Excellence, Nippon Medical School Hospital, Tokyo, Japan.

ORCID-Profile: Keina Yomono, Dinesh Khanna, Masataka Kuwana

Förderung

  • Ministry of Health, Labour and Welfare

Zitieren

APA

Yomono, K., Huang, S., Khanna, D., & Kuwana, M. (2026). Performance of Circulating Inflammatory Biomarkers and Krebs von den Lungen 6 for Predicting Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease. ACR Open Rheumatology, 8(3). https://doi.org/10.1002/acr2.90013

Vancouver

Yomono K, Huang S, Khanna D, Kuwana M. Performance of Circulating Inflammatory Biomarkers and Krebs von den Lungen 6 for Predicting Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease. ACR Open Rheumatology. 2026;8(3). doi:10.1002/acr2.90013

BibTeX
@article{Yomono2026,
  author = {Yomono, Keina and Huang, Suiyuan and Khanna, Dinesh and Kuwana, Masataka},
  title = {Performance of Circulating Inflammatory Biomarkers and Krebs von den Lungen 6 for Predicting Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease},
  journal = {ACR Open Rheumatology},
  year = {2026},
  volume = {8},
  number = {3},
  doi = {10.1002/acr2.90013}
}
Kostenlos starten →